Condition: Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer · Sponsor: AbbVie
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous epithelial ovarian, fallopian tube or primary peritoneal cancer (EOC). Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to cancer cells carrying a protein called folate receptor alpha (FRα). This is a single arm study in adult participants with advanced-stage Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) III-IV FRα-expressing serous EOC. Around 140 participants will be enrolled in the study at approximately 80 sites in the United States. Participants will receive intravenous infusion of MIRV in combination with carboplatin on day 1 of each cycle, every 21 days for up to 6 - 9 Cycles. The total study duration will be approximately 3 years . There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham (UAB) Hospital /ID# 274793 | Birmingham, Alabama, United States | Recruiting |
| Usa Mitchell Cancer Institute /ID# 276022 | Mobile, Alabama, United States | Recruiting |
| University of California Los Angeles Medical Center /ID# 274566 | Los Angeles, California, United States | Recruiting |
| Scripps Md Anderson - Prebys Cancer Center /ID# 276891 | San Diego, California, United States | Recruiting |
| California Pacific Medical Center - Van Ness Campus /ID# 275329 | San Francisco, California, United States | Recruiting |
| Ridley Tree Cancer Center /ID# 275219 | Santa Barbara, California, United States | Active Not Recruiting |
| Danbury Hospital, Western Connecticut Health Network /ID# 274783 | Danbury, Connecticut, United States | Recruiting |
| Yale University School of Medicine /ID# 275794 | New Haven, Connecticut, United States | Recruiting |
| Norwalk Hospital /ID# 274561 | Norwalk, Connecticut, United States | Recruiting |
| Jupiter Medical Center /ID# 276616 | Jupiter, Florida, United States | Recruiting |
| Mount Sinai Medical Center /ID# 274868 | Miami Beach, Florida, United States | Recruiting |
| Rush Md Anderson Cancer Center /ID# 274926 | Chicago, Illinois, United States | Recruiting |
+ 55 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06890338